Cansino Biologics688185.SHValuation Analysis

As of Oct 19, 2026, Cansino Biologics (688185.SH) trades at a P/E of 504.00x, P/B of 4.12x, P/S of 18.60x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 82nd percentile over the trailing 10Y window (vs. 41st percentile over 3Y); P/B sits at the 55th percentile over the trailing 10Y window (vs. 94th percentile over 3Y); P/S sits at the 29th percentile over the trailing 10Y window (vs. 42nd percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 98th percentile within its industry and the 97th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
Notably, P/E and P/B aren't telling quite the same story, 26.1 points apart — worth checking the full percentile matrix on this page for the complete picture. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Cansino Biologics operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.